# Milestone Scientific Inc.: Form 10-Q for the period ended Mar 31, 2020

- Company: [Milestone Scientific Inc.](/companies/mlss.md) (CIK 855683)
- Form: 10-Q
- Filed: 2020-05-15
- Accepted by EDGAR: May 15, 2020, 16:16 ET
- Period: 2020-03-31
- Accession: 0001437749-20-011007
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/855683/000143774920011007/mlss20200331_10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/855683/000143774920011007/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2020-03-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2020-01-01 to 2020-03-31 | $1.8m | us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax |
| Cost of revenue | 3 months, 2020-01-01 to 2020-03-31 | $527.3k | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months, 2020-01-01 to 2020-03-31 | $1.3m | us-gaap:GrossProfit |
| Research and development | 3 months, 2020-01-01 to 2020-03-31 | $107.5k | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2020-01-01 to 2020-03-31 | $2.8m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2020-01-01 to 2020-03-31 | −$1.6m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2020-01-01 to 2020-03-31 | $250 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2020-01-01 to 2020-03-31 | −$1.6m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.03 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2020-01-01 to 2020-03-31 | −$0.03 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2020-01-01 to 2020-03-31 | 49,730,252 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months, 2020-01-01 to 2020-03-31 | −$971.1k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months, 2020-01-01 to 2020-03-31 | $7.1k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2020-03-31 | $766.0k | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2020-03-31 | $5.3m | us-gaap:AssetsCurrent |
| Total assets | at 2020-03-31 | $6.4m | us-gaap:Assets |
| Current liabilities | at 2020-03-31 | $5.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2020-03-31 | $5.9m | us-gaap:Liabilities |
| Shareholders' equity | at 2020-03-31 | $567.8k | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 25,373 characters.

The following discussions of the financial condition and results of operations should be read in conjunction with the financial statements and the notes to those statements contained in this report and in connection with management's discussion and analysis and the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2019, which was filed with the Securities and Exchange Commission, or SEC on March 30, 2020. Certain statements in this discussion and elsewhere in this report constitute forward-looking statements, within the meaning of section 21E of the Exchange Act, that involve risks and uncertainties. The actual results may differ materially from those anticipated in these forward-looking statements.

### OVERVIEW

Our common stock was listed on the NYSE American on June 1, 2015 and trades under the symbol “MLSS”. We have developed a proprietary, computer-controlled anesthetic delivery instrument, using The Wand, a single use disposable handpiece. The instrument is marketed in dental sector under the trademark CompuDent®, and STA Single Tooth Anesthesia System and in medical sector under the trademark CompuMed. CompuDent is suitable for all dental procedures that require local anesthetic. CompuMed is suitable for many medical procedures regularly performed in plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, orthopedics and several other disciplines. The dental instruments are sold in the United States, U.S. territories, Canada, and in over 58 other countries abroad. In June 2017, the FDA approved our 510(k) applications for marketing clearance in the United States of our CompuFlo Epidural Computer Controlled Anesthesia System. We are in the process of introductory meetings with medical device distributors within the United States and Europe. There have been five medical instruments sold in the United States in 2018 and limited amounts sold internationally as of the reporting date. Certain of our medical instruments have obtained European CE mark approval and can be marketed and sold in most European countries.

On January 24, 2019, the Company received a letter from the NYSE- American Exchange (Exchange) stating that the Company’s Plan has been accepted by the Exchange. The Company is still not in compliance with Section(s) 1003(a)(i), (ii) and (iii) of the Company Guide and its listing on the Exchange is being continued pursuant to an extension granted by the Exchange. If the Company is not in compliance with the continued listing standards by May 20, 2020, or if the Company does not make progress consistent with the Plan, the Exchange will initiate delisting procedures as appropriate. The Company may appeal a staff delisting determination in accordance with Section 10 and Part 12 of the Exchange's guide.

Milestone Scientific remains focused on advancing efforts to achieve the following five primary objectives:

- Establishing Milestone’s DPS Dynamic Pressure Sensing technology platform as the standard-of-care in painless and precise drug delivery, providing for the first time, objective visual and audible in-tissue pressure feedback, and continuing to expand platform applications;
- Following obtaining successful FDA clearance of our first medical devices, Milestone Scientific is transitioning from a research and development organization to a commercially focused medical device company;
- Expanding our global footprint of our CompuFlo Epidural System by partnering with distribution companies worldwide; and
- Continuing the development of our proprietary cosmetic injection device for delivery of botulinum toxin (such as Botox® and Dysport®)

### Wand STA Dental Market

Since its market introduction in early 2007, the Wand/STA Instrument and prior C-CLAD products have been used to deliver over 66 million safe, effective and comfortable injections. The instrument has also been favorably evaluated in numerous peer-reviewed, published clinical studies and associated articles. Moreover, there appears to be a growing consensus among users that the STA Instrument is proving to be a valuable and beneficial instrument that is positively impacting the practice of dentistry worldwide.

Beginning January 1, 2016, Milestone Scientific entered into a non-exclusive distribution agreement with Henry Schein, Inc. (“Henry Schein”). In June 2016, that agreement was replaced with an exclusive distribution arrangement for our dental products for the United States and Canada with Henry Schein. Under this arrangement we have a semi-dedicated independent sales force visiting dentists.

To date, Henry Schein has endeavored to accomplish the goals set forth in the exclusive distribution agreement for *The Wand* STA instrument and handpieces, including training of its exclusive products sale’s specialists. Specifically, up to 25 exclusive product sales specialists have now been fully trained as experts in the features, advantages and benefits of *The Wand/*STA instrument and handpieces and all are currently in the field selling the instrument.

Henry Schein increased the number of exclusive product specialist in 2019 and trained an additional customer service representative to support dentists across North America through its exclusive product sales customer call center, as business volume increases.

On the global front, we have granted exclusive marketing and distribution rights for the Wand/STA Instrument to select dental suppliers in various international regions in Asia, Africa, South America and Europe. They include FM Produkty Dla Stomatologii in Poland and Unident AB in the Scandinavian countries of Denmark, Sweden, Norway and Iceland.

In October 2012, the State Food and Drug Administration (CFDA) of the People’s Republic of China approved our Wand/STA *Single Tooth Anesthesia System* (STA System). In May 2014, the CFDA also approved the Wand STA handpieces for sale in China.

### Medical Market

In September 2014, Milestone Medical received CE clearance to distribute their epidural and intra-articular instruments in the European Community (EU). Milestone Medical signed a distribution agreement in March 2015 with a medical distributor in Poland for the distribution of the epidural instrument. This distribution agreement was terminated in late 2016 due to the distributor’s inadequate performance under the distribution agreement. Milestone Medical is continuing to pursue distributors for the instrument in the EU community.

During 2016, Milestone Scientific filed for 510(k) marketing clearance with the U.S. Food and Drug Administration (FDA) for both intra-articular and epidural injections with the CompuFlo Epidural System. In June 2017, the FDA approved the CompuFlo Epidural System for epidural injections. Milestone Scientific is in the process of meeting with medical device distributors within the United States and foreign markets. Milestone Scientific’s immediate focus is on marketing its epidural device throughout the United States and Europe.

In December 2016, we received notification from the FDA that based upon the 510(k)-application submitted for intra- articular injections, we did not adequately document that the device met the equivalency standard required for 510(k) clearances. Following consultation with the FDA Office of Device Evaluation, we filed a new 510(k) application for the device in June 2018. In August 2018, the FDA provided Milestone Scientific with a list of questions on the intra-articular 510(k) application filed in June 2018. Due to the delay in responding to FDA questions Milestone Scientific will be required file a new 510(K) application.

In January 2019, the Company announced the results of a four hundred patient clinical trial by researchers from the University of Miami, University of Texas and Northwestern University, and two prominent California-based pain clinics. Published-Ahead-of-Print in Anesthesia & Analgesia (the official Journal of the International Anesthesia Research Society), the randomized, controlled study compared the effectiveness of the CompuFlo Epidural System in labor and delivery and chronic pain management, where loss of resistance and fluoroscopy are the current standards of care. The CompuFlo Epidural System was found to be ninety-nine percent successful in objectively identifying the epidural space even in challenging patients with a higher body mass index.

In February 2019, the Company announced a new 120-patient clinical study published in Anesthesiology Research & Practice that verifies the CompuFlo Epidural System consistently differentiates false loss of resistance from true loss of resistance during epidural placement. In all cases where the CompuFlo Epidural System’s pressure measurements were used to objectively identify the epidural space, the block was performed successfully with no complications.

In February 2019, the Company announced Ospedale “Pugliese Ciaccio” di Catanzaro is the first hospital in Italy to use the CompuFlo Epidural System for all epidurals in labor and delivery. For a local hospital performing a limited number of epidurals, the CompuFlo Epidural System offers a real-time, objective tool for accurate epidural space identification to help reduce failure rates and accidental dural punctures that can require further treatment and interventions.

In April, 2019 the Company entered the medical education market with the introduction of the CompuFlo® Epidural Trainer (CompuFlo Trainer), an instructional instrument that uses pressure sensing technology to improve epidural placement success. The Company has signed an agreement to distribute the CompuFlo Trainer with American 3B Scientific, a leading supplier of didactic material for medical education.

In June 2019 the Company announced the results of two research abstracts featuring the CompuFlo Epidural device at Euroanesthesia 2019, Europe's largest annual event showcasing the latest knowledge in the field of anesthesia. The abstracts were presented during scientific poster sessions highlighting how CompuFlo's objective detection of tissue pressure makes challenging procedures with difficult patients more efficient and accelerates clinical competency for trainee.

In October 2019, the Company announced the first international multicenter study to compare the incidence of accidental dural puncture using the CompuFlo Epidural System versus the continuous loss of resistance (LOR) technique. The study collected records between 2015 and 2019 of epidural administration on labor and delivery patients using the CompuFlo Epidural System from four institutions, one in the U.S., one in Chile, and two from Italy. Among the four sites, there were 812 patients who received epidural analgesia with CompuFlo and none had accidental dural puncture regardless of the composition of the epidural performer types. The Company also announced that Professor Rovnat Babazade, MD, University of Texas Medical Branch at Galveston, Department of Anesthesiology, presented a poster at the ANESTHESIOLOGY® 2019 Annual Meeting in Orlando, Florida, entitled, "International Multicenter Study of Accidental Dural Puncture Rate; Comparison of the CompuFlo with Traditional Method''. ANESTHESIOLOGY 2019, hosted by the American Society of Anesthesiologists (ASA), unites more than 14,000 clinicians, thought leaders and professionals from around the world.

In November 2019, the Company and 3B Scientific, the world's leading supplier of didactic material for medical education, signed a global agreement expanding distribution of the CompuFlo Trainer. The expanded agreement allows 3B Scientific to capitalize on momentum from strong interest in the CompuFlo Trainer at its unveiling at Euroanesthesia 2019 and the Association of Women's Health, Obstetric and Neonatal Nurses meeting, and gives more anesthesia instructors the ultimate solution to accelerate the epidural procedure's learning curve and trainee success.

The following table shows a breakdown of Milestone Scientific’s product sales (net), domestically and internationally, by business segment product category:

| Domestic-US & Canada | March 31, 2020 Dental | Medical | Total |
| --- | ---: | ---: | ---: |
| Devices | $525 | $- | $525 |
| Handpieces | 697,360 | - | 697,360 |
| Other | 22,506 | - | 22,506 |
| **Total Domestic US & Canada** | $720,391 | $- | $720,391 |
| **International ROW** |  |  |  |
| Devices | $242,504 | $7,600 | $250,104 |
| Handpieces | 830,208 | 200 | 830,408 |
| Other | 10,483 | - | 10,483 |
| **Total International-ROW** | $1,083,195 | $7,800 | $1,090,995 |
| **International-China** |  |  |  |
| Devices | $- | $- |  |
| Handpieces | - | - | - |
| Other | - | - | - |
| **Total International** | $- | $- | $- |
| **Total Product Sales** | $1,803,586 | $7,800 | $1,811,386 |

| Domestic-US & Canada | March 31, 2019 Dental | Medical | Total |
| --- | ---: | ---: | ---: |
| Devices | $123,994 | $- | $123,994 |
| Handpieces | 789,153 | 400 | 789,553 |
| Other | 16,817 | - | 16,817 |
| **Total Domestic US & Canada** | $929,964 | $400 | $930,364 |
| **International ROW** |  |  |  |
| Devices | $285,345 | $- | $285,345 |
| Handpieces | 631,311 | - | 631,311 |
| Other | 18,889 | - | 18,889 |
| **Total International-ROW** | $935,545 | $- | $935,545 |
| **International-China** |  |  |  |
| Devices | $- | $- | $- |
| Handpieces | 50,000 | - | 50,000 |
| Other | - | - | - |
| **Total International** | $50,000 | $- | $50,000 |
| **Total Product Sales** | 1,915,509 | 400 | 1,915,909 |

27

### Current Product Platform

See Note 1 Organization and Business.

### Results of Operations

The following table sets forth the consolidated results of operations for the three months ended March 31, 2020 compared to 2019. The trends suggested by this table may not be indicative of future operating results:

| Operating results: | For three months ended March 31, 2020 | 2019 |
| --- | ---: | ---: |
| Product sales, net | $1,811,386 | $1,915,909 |
| Cost of products sold | 527,250 | 618,694 |
| Gross profit | 1,284,136 | 1,297,215 |
| Operating expenses: |  |  |
| Selling, general and administrative expenses | 2,785,262 | 2,109,050 |
| Research and development expenses | 107,480 | 6,346 |
| Loss from operations | (1,608,606) | (818,181) |
| Other income, and loss on earning net | (4,347) | 24,986 |
| Net loss | (1,612,953) | (793,195) |
| Net loss attributable to noncontrolling interests | (12,738) | (10,443) |
| Net loss attributable to Milestone Scientific Inc. | $(1,600,215) | $(782,752) |

| Cash flow: | March 31, 2020 | March 31, 2019 |
| --- | ---: | ---: |
| Net cash used in operating activities | $(972,079) | $(220,171) |
| Net cash used in investing activities | (7,138) | (8,104) |
| Net cash provided by financing activities | 228,920 | 2,224,546 |

### Three months ended March 31, 2020 compared to Three months ended March 31, 2019

### Net sales for 2020 and 2019 were as follows:

|  | 2020 | 2019 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,803,586 | $1,915,509 | $(111,923) | -6% |
| Medical | 7,800 | 400 | 7,400 | 1850% |
| Total sales, net | $1,811,386 | $1,915,909 | $(104,523) | -5% |

Consolidated revenue for the three months ended March 31, 2020 and 2019 were approximately $1.8 million and $1.9 million, respectively. Dental revenue for the three months ended March 31, 2020 and 2019 were approximately $1.8 million and $1.9 million, respectively. Dental revenues decreased by approximately $112,000, which was related to a decrease in devices and handpiece sales in the United States and Canada by approximately $272,000, primarily due to a slower demand for the STA instruments, and decrease in Milestone China revenue recognition of approximately $50,000, offset by an increase in international sales by approximately $219,000, in the three months ended March 31, 2020 compared to 2019. The reduction in shipments to Milestone China is due to Milestone China’s continuing cash flow issues and the modification to their business strategy to better serve the China dental market.

Medical revenue for the three months ended March 31, 2020 and 2019, were approximately $7,800 and $400, respectively. In June 2017, the Company announced that the CompuFlo Epidural System received 510(k) marketing clearances from the U.S. Food and Drug Administration (FDA). Milestone is in the process of attending medical device trade shows and attending introductory meetings with medical device distributors within the United States and European markets. The Company is focusing the marketing its Epidural devices principally in the United States. In 2020, the Company began to build an internal sales force to market Epidural devices to hospitals and medical center throughout the United States.

As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world due to the continuing spread of COVID-19, we anticipate that our revenue for the second quarter, and possibly the third quarter, will be materially and adversely affected. At this point in time, it is too early to determine an estimate of what the second or third quarter impact will be or the effect COVID-19 may have on our fourth quarter revenue. In addition, it is too early to determine what the effect will be on the anticipated commercialization of our CompuFlow Epidural system as a medical device in 2020

### Gross Profit for 2020 and 2019 were as follows:

|  | 2020 | 2019 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $1,279,845 | $1,296,842 | $(16,997) | -1% |
| Medical | 4,291 | 373 | 3,918 | 1050% |
| Total gross profit | $1,284,136 | $1,297,215 | $(13,079) | -1% |

Consolidated gross profit for the three months ended March 31, 2020 and 2019 approximately 71% and 68%, respectively.

### Selling, general and administrative expenses for 2020 and 2019 were as follows:

|  | 2020 | 2019 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $703,459 | $804,180 | $(100,721) | -13% |
| Medical | 566,625 | 486,406 | 80,219 | 16% |
| Corporate | 1,515,178 | 818,464 | 696,714 | 85% |
| Total selling, general and administrative expenses | $2,785,262 | $2,109,050 | $676,212 | 32% |

Consolidated selling, general and administrative expenses for the three months ended March 31, 2020 and 2019, were approximately $2.8 million and $2.1 million, respectively. The increase of approximately $676,000 is categorized in several areas. Professional Fees increased by approximately $487,000 due to the Company seeking business alternatives in addition to possible capital funding. Office expense increased approximately $143,000 for the relocation of the company office and other related costs. As a result of the reduced hours and closings of dental offices throughout the country and the rest of the world due to the continuing spread of COVID-19, salaries, and marketing expenses decreased approximately $46,000 compared to 2019.

### Research and Development for 2020 and 2019 were as follows:

|  | 2020 | 2019 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $- | $696 | $(696) | 100% |
| Medical | 107,480 | 5,650 | 101,830 | 1802% |
| Corporate | - |  | - | 0% |
| Total research and development | $107,480 | $6,346 | $101,134 | 1594% |

Consolidated research and development expenses for the three months ended March 31, 2020 and 2019, were approximately $107,000 and $6,000, respectively. The increase is due to additional development costs and software upgrades associated with the Epidural devices.

### Profit (Loss) from Operations for 2020 and 2019 were as follows:

|  | 2020 | 2019 | Increase Decrease% |  |
| --- | ---: | ---: | ---: | ---: |
| Dental | $576,386 | $491,966 | $84,420 | 17% |
| Medical | (669,814) | (491,683) | (178,131) | 36% |
| Corporate | (1,515,178) | (818,464) | (696,714) | 85% |
| Total loss from operations | $(1,608,606) | $(818,181) | $(790,425) | 97% |

The loss from operations was approximately $1.6 million and $818,000 for the first quarter ending March 31, 2020 and 2019 respectively. The increase in the loss quarter over quarter is due to an increase in selling, general and administration expenses of approximately $676,000 and an increase of approximately $101,000 in research and development as noted in the previous section of this report. The dental segments are still the primary revenue and gross profit generator for the Company. The dental segment has consistent revenue in the United States and Rest of the World and manage expenses during the process. Costs in the medical segment are beginning to increase as personnel are expanded in the U.S. to focus on our domestic Epidural device business.

### Liquidity and Capital Resources

At March 31, 2020, Milestone Scientific had cash and cash equivalents of approximately $766,000 and working capital of approximately $21,000 versus working capital of $1.2 million at December 31, 2019. For the three months ended March 31, 2020, we had negative cash flows from operating activities of approximately $972,000 compared to $220,000 for the three months ended March 31, 2019. Based on current and expected cash to be used in operating activities substantial doubt exists about the Company’s ability to continue as a going concern for at least the next twelve months from the financial reporting date.

Milestone Scientific is actively pursuing the generation of positive cash flows from operating activities through an increase in revenue from its dental business worldwide, the generation of revenue from its medical devices and disposables business in the United States and worldwide, as well as considering other strategic plans or transactions. However, the COVID-19 pandemic is expected to have an adverse effect on the Company’s operations and cash flows for at least in the next two quarters and possibly longer depending on the length and severity in of the pandemic in important dental markets.

Management is also actively pursuing additional financing and/or other strategic plans and transactions but can provide no assurances that such financing or other strategic plans will be available on acceptable terms, or at all. Further, the extreme volatility in the financial markets due to COVID-19, as well as the expected non-compliance with the NYSE May 20th, 2020 requirement may make it more difficult to raise sufficient capital when needed or execute other strategic plans or transactions. Without additional funding a delay, scale back or elimination of some or all of the Company’s medical commercial strategy or development programs could be required, all of which could have a material adverse impact on the Company.

The capital raised in April 2020 (see Note 14 – Subsequent Events) provides Milestone Scientific with working capital to continue marketing of the CompuFlo Epidural device and to market its dental devices. Now that the CompuFlo Epidural System has obtained FDA clearance in the United States (June 2017), the development costs were reduced in 2019 but the selling costs are expected to continue to increase. The FDA clearance has provided the Company with the opportunity to establish distribution in the U.S. At the same time, the Company is looking to establish additional financing to support the Epidural device commercialization process. The intra-articular device will restart the 510K application process later this year, subject to sufficient funding.

On April 14, 2020, the Company closed its previously announced underwritten offering of 4,750,000 shares of its common stock and warrants to purchase up to an aggregate of 2,375,000 shares of the its common stock. Each share of common stock was sold together with a warrant to purchase 0.50 of one share of common stock at a combined price to the public of $0.95. Gross proceeds before underwriting discounts commissions and estimated offering expenses, were approximately $4.5 million. In addition, Milestone Scientific granted to Maxim Group LLC a 45-day option to purchase up to an additional 712,500 shares of common stock and/or warrants to purchase up to 356,250 shares of common stock for the purposes of covering any over-allotments, at the public offering price less discounts and commissions, of which Maxim Group LLC partially exercised its option to purchase 200,000 shares of common stock and warrants to purchase up to 330,000 shares of common stock. The partial over-allotment exercise transaction also closed on April 14, 2020, bringing the total net proceeds of the offering, after underwriting discounts and commissions and estimated offering expenses, to approximately $4.3 million. The warrants are immediately exercisable at a price of $1.20 per share of common stock and expire three years from the date of issuance. The shares of common stock and the accompanying warrants were purchased together in the offering but were issued separately and were immediately separable upon issuance.

In connection with capital raise on April 14, 2020, Maxim exercised its over-allotment option under the Underwriting Agreement, and purchased 470,000 shares of common stock, less the Underwriter's discount and commissions and offering expenses, of $415,244. This over-allotment exercise transaction closed on April 17, 2020.

## Market risk

As filed, 162 characters.

Milestone Scientific is a “smaller reporting company” as defined by Regulation S-K and, as such, is not required to provide the information required by this item.

## Controls and procedures

As filed, 1,312 characters.

Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have evaluated the effectiveness of the design and operation of Milestone Scientific’s disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of the end of the period covered by this report. Based upon that evaluation, Milestone Scientific’s Interim Chief Executive Officer and Chief Financial Officer have concluded that the disclosure controls and procedures as of March 31, 2020 are effective to ensure that information required to be disclosed in the reports Milestone Scientific files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that such information is accumulated and communicated to Milestone Scientific's management, including the Interim Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There have been no changes in Milestone Scientific’s internal control over financial reporting that occurred during Milestone Scientific’s last fiscal quarter that have materially affected, or that are reasonably likely to materially affect, Milestone Scientific’s internal controls over financial reporting.

Filed May 15, 2020.
Source: SEC EDGAR, the filing index for accession 0001437749-20-011007. Last ingested by Listed: Nov 14, 2026, 11:14 ET. No prices; not investment advice.
